[go: up one dir, main page]

PE20161366A1 - Heterociclil-sulfonas sustituidas con heteroarilo - Google Patents

Heterociclil-sulfonas sustituidas con heteroarilo

Info

Publication number
PE20161366A1
PE20161366A1 PE2016002003A PE2016002003A PE20161366A1 PE 20161366 A1 PE20161366 A1 PE 20161366A1 PE 2016002003 A PE2016002003 A PE 2016002003A PE 2016002003 A PE2016002003 A PE 2016002003A PE 20161366 A1 PE20161366 A1 PE 20161366A1
Authority
PE
Peru
Prior art keywords
heteroaryl
substituted
heterociclyl
sulphones
compounds
Prior art date
Application number
PE2016002003A
Other languages
English (en)
Inventor
Kathy Mackenzie
Marc Rogers
Achim Kless
Stefan Schunk
Nils Damann
Florian Jakob
Melanie Reich
Michael Haurand
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20161366A1 publication Critical patent/PE20161366A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se refiere a compuestos de formula I, donde: m es 1 o 2; n es 0 o 1; Y es un enlace o –C(R3)2-; R3 es H, alquilo C1-C6, entre otros; L es –[C(R4)2]x-(X)y-[C(R4)]z-; x es 0, 1 o 2; y es 0 o 1; z es 0 o 1; R4 es H, alquilo C1-C6, entre otros; X es O, S, S(O)2, entre otros; R1 es H, F, Cl, entre otros; R2 es H, F, Cl, entre otros; Ar1 y Ar2 son arilo o heteroarilo sustituidos. Son compuestos preferidos: 3-MetIlsulfonIl-5-[4-metIl-4-[[3-(trifluorometil)fenil]sulfonil]-tetrahidro-piran-2-il]- piridina; 5-Ciclopropil-2-[4-metil-4-[[3-(trifluorometil)fenil]sulfonil]-tetrahidro-piran-2-il]-piridina; entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos son bloqueadores de los canales de calcio dependientes de voltaje, siendo utiles en el tratamiento y/o profilaxis del dolor
PE2016002003A 2014-04-14 2015-04-14 Heterociclil-sulfonas sustituidas con heteroarilo PE20161366A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14001346 2014-04-14

Publications (1)

Publication Number Publication Date
PE20161366A1 true PE20161366A1 (es) 2017-01-15

Family

ID=50486704

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016002003A PE20161366A1 (es) 2014-04-14 2015-04-14 Heterociclil-sulfonas sustituidas con heteroarilo

Country Status (16)

Country Link
US (2) US9879000B2 (es)
EP (2) EP3495360A1 (es)
JP (1) JP6673850B2 (es)
KR (1) KR20160144487A (es)
CN (1) CN106458956B (es)
AR (1) AR100073A1 (es)
AU (1) AU2015246387B2 (es)
BR (1) BR112016023860A2 (es)
CA (1) CA2945535A1 (es)
CL (1) CL2016002615A1 (es)
EA (1) EA032581B1 (es)
IL (1) IL248250A0 (es)
MX (1) MX2016013447A (es)
PE (1) PE20161366A1 (es)
TW (1) TW201620899A (es)
WO (1) WO2015158427A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EA032638B1 (ru) * 2014-04-14 2019-06-28 Грюненталь Гмбх Арилзамещенные гетероциклилсульфоны
TW201726128A (zh) * 2015-10-08 2017-08-01 歌林達有限公司 經吡唑基取代之四氫哌喃基碸
TW201718557A (zh) * 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸
KR102269305B1 (ko) 2016-06-13 2021-06-25 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
PL3600309T3 (pl) 2017-03-28 2022-11-07 Gilead Sciences, Inc. Skojarzenia terapeutyczne do leczenia chorób wątroby
MX2021006696A (es) 2018-12-06 2021-07-07 Daiichi Sankyo Co Ltd Derivado de cicloalcano-1,3-diamina.
HRP20240265T1 (hr) 2019-01-15 2024-05-10 Gilead Sciences, Inc. Spoj izoksazola kao fxr agonist i farmaceutski pripravci koji ga sadrže
CN118388473A (zh) 2019-02-19 2024-07-26 吉利德科学公司 Fxr激动剂的固体形式
MA56053A (fr) * 2019-10-18 2022-04-20 Fmc Agro Singapore Pte Ltd Procédés de préparation d'acide 5-bromo-2-(3-chloro-pyridin-2-yl)-2h-pyrazole-3-carboxylique
BR112022007294A2 (pt) * 2019-10-18 2022-07-05 Fmc Corp Métodos para a preparação de ácido 5-bromo-2-(3-cloro-piridin-2-il)-2h-pirazol-3-carboxílico

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1138680A1 (en) * 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
WO2007125398A2 (en) * 2006-04-27 2007-11-08 Pfizer Japan Inc. : sulfonamide compounds as antagonists of the n-type calcium channel
GB0813142D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
NZ598269A (en) * 2009-09-18 2014-12-24 Zalicus Pharmaceuticals Ltd Aryl sulphone derivatives as calcium channel blockers
EA032638B1 (ru) * 2014-04-14 2019-06-28 Грюненталь Гмбх Арилзамещенные гетероциклилсульфоны
TW201726128A (zh) 2015-10-08 2017-08-01 歌林達有限公司 經吡唑基取代之四氫哌喃基碸
TW201718557A (zh) 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸

Also Published As

Publication number Publication date
JP6673850B2 (ja) 2020-03-25
MX2016013447A (es) 2017-01-18
US9926302B2 (en) 2018-03-27
CN106458956A (zh) 2017-02-22
CA2945535A1 (en) 2015-10-22
AU2015246387B2 (en) 2018-11-22
KR20160144487A (ko) 2016-12-16
WO2015158427A1 (en) 2015-10-22
EP3495360A1 (en) 2019-06-12
AU2015246387A1 (en) 2016-12-01
US20150291572A1 (en) 2015-10-15
BR112016023860A2 (pt) 2017-08-15
US9879000B2 (en) 2018-01-30
JP2017511352A (ja) 2017-04-20
CN106458956B (zh) 2019-06-14
US20170121314A1 (en) 2017-05-04
CL2016002615A1 (es) 2017-04-28
EP3131894A1 (en) 2017-02-22
AR100073A1 (es) 2016-09-07
EA032581B1 (ru) 2019-06-28
IL248250A0 (en) 2016-11-30
EA201692049A1 (ru) 2017-04-28
TW201620899A (zh) 2016-06-16

Similar Documents

Publication Publication Date Title
PE20161366A1 (es) Heterociclil-sulfonas sustituidas con heteroarilo
CY1122542T1 (el) Νεα παραγωγα υδροξυεστερα, μια διεργασια για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1123645T1 (el) Δικυκλικα παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1124496T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
EA202091484A1 (ru) 4-азаиндольные соединения
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
CY1124620T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
MX2019004578A (es) Oxisteroles y metodos de uso de los mismos.
PE20171329A1 (es) Agentes inmunorreguladores
UY36056A (es) “compuestos de heteroarilo o arilo bicíclicos fusionados “.
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
MX2017002670A (es) Inhibidores de glucosidasa.
EA201791304A1 (ru) Производные изохинолина для лечения вич
MA40281B1 (fr) Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
PE20161438A1 (es) Inhibidores de desmetilasa 1 especifica a lisina
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
EA201690135A1 (ru) Трициклические соединения бензоксаборола и их применение
MX376062B (es) Agonistas del receptor muscarinico.
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
PE20142461A1 (es) Moduladores del receptor de estrogeno y sus usos
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
CY1120325T1 (el) Τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις φωσφοϊνοσιτιδιου 3-κινασης
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
PE20191478A1 (es) Compuestos moduladores del receptor de hidorcarburos de arilo (ahr)